zPREDICTA Collaborates With Science Exchange To Offer Unique Patient-Derived Cell Culture Services To Drug Development Researchers
PALO ALTO, Calif.–(BUSINESS WIRE)–Science Exchange, the world’s leading marketplace for outsourced R&D, has announced that it is working with zPREDICTA to offer online access to its predictive cancer drug development and testing services.
California-based company zPREDICTA™ has created a novel technology that reconstructs physiologically-relevant organ-specific human microenvironments that help eliminate the guesswork from drug development. Meaningful drug discovery studies involve complex experiments that are not feasible to perform manually. Automation is the answer, improving accuracy, saving time and reducing the amount of compound used.
Metastasis in 3D: How Ixchel’s (zPREDICTA) 3D Tissue Model Mimics Metastasis For Screening Cancer Therapies
Current in vivo and in vitro models for testing cancer therapeutics don’t accurately model the progression of metastasis, which limits their ability to predict efficacy in patients. Ixchel’s (zPREDICTA) PD-3D system is a cell-based 3D model that mimics the spread of cancer in human tissues, and aims to predict the clinical success of cancer therapies more reliably than other models.
Ixchel Scientific (now zPREDICTA) (YC S15) Can Predict How The Human Body Will React To Cancer Drugs
Ixchel Scientific, a startup launching out of our current class, is making a tool that aims to more accurately predict how cancer drugs will behave in the body by creating organ-specific testing environments.